AngioDynamics tops estimates as revenue rises and losses narrow, driven by Med Tech demand, even as gross margin slips.

AngioDynamics Inc (ANGO) reports robust revenue increases across key segments, but faces ongoing financial pressures and margin declines.

AngioDynamics, Inc. ( ANGO) Q3 2026 Earnings Call April 2, 2026 8:00 AM EDT Good morning, and welcome to the AngioDynamics Fiscal Year 2026 Third Quarter Earnings Call. [Operator Instructions] As a ...

AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2026 Earnings Call Transcript April 2, 2026 AngioDynamics, Inc. misses on earnings ...

The strong performance was driven by the company’s mechanical thrombectomy portfolio, including AlphaVac and AngioVac, which grew 17.9%, while Auryon sales increased 17.9% and NanoKnife sales jumped ...

Management raised FY2026 net sales guidance to $313.5 million to $315.5 million (from $312 million to $314 million) and raised adjusted EBITDA guidance to $10 million to $12 million (from $8 million ...